Clinical Trials

Women's Cardiovascular Health 
Peripartum Hypertension and Cardiac Assessment of Remodeling Evaluation (P-CARE)

General Surgery | Ventral Hernia

A Prospective Study Evaluating the Clinical Outcomes of Ventral Hernias treated Robotically with OviTex® Reinforced Tissue Matrix
 

Structural

A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation

Amyloidosis

Cardiac Amyloidosis Registry Study ("CARS")

Amyloidosis

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Amyloidosis

A Non-interventional, Prospective, Multi-country Study Collecting Realworld Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis

Aortic Stenosis

Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients who have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement

Aortic Stenosis

SAPIEN 3/SAPIEN 3 Ultra/SAPIEN 3 Ultra RESILIA Moderate AS PROGRESS Trial Access

Aortic Valve

RESTORE Study (REdo tranScatheter aortic valve replacement for Transcatheter aOrtic valve failuRE)
 

Neurology | Ischemic Stroke

Statins use in intracerebral hemorrhage patients

Neurosurgery

Evaluating the Impact of 3D Printed Spine Models on Patient Understanding and Satisfaction

Nursing | Post-ICU Delirium

Simultaneous Recumbent Cycling and Cognitive Training on Cognition in Intensive Care Unit Survivors: A Randomized Control Trial

Advanced Solid Tumors

First-in-Human Study of STX-478, a H1047X Mutation-specific PI3Kα Inhibitor as Monotherapy and in Combination with Other Antineoplastic Agents in Advanced Solid Tumor Patients Tumors

Advanced Solid Tumors

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Breast Cancer

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Breast Cancer

Phase 3 open label study comparing efficacy and safety of the combination of lasofoxifene and abemaciclib to the combination of fulvestrant and abemaciclib for the treatment of adults with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation

Breast Cancer 

De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Breast Cancer 

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment

Breast Cancer 
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer 
A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer 

Breast Cancer 
A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations

Breast Cancer | Solid Tumors
Phase 1a/1b Study of the PI3Kα:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)

Colorectal Cancer 
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
 

Colorectal Cancer 
M24-533: A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with ABBV-400 in Subjects with Metastatic Colorectal Cancer– Feasibility Request

Gastrointestinal Cancer

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2, D9802C00001.